Why the study?
Recent data support the predictive value of cardiac biomarkers for mortality and cardiotoxicity in cancer patients, prompting an overview of cardiac troponins in identifying high-risk patients.
Does cardiac troponin measurement predict all-cause mortality and cardiotoxicity in asymptomatic cancer patients?
Does cardiac troponin measurement predict all-cause mortality and cardiotoxicity in asymptomatic cancer patients?
Cardiac troponin measurement is a valuable tool for risk stratification and predicting cardiotoxicity in asymptomatic cancer patients before treatment.
Answers are grounded in this paper and cite their sources.
May support pre-treatment risk stratification in cancer patients; leaves open prospective validation before routine adoption.
Recent data support the predictive value of cardiac biomarker for all-cause mortality and cardiotoxicity in cancer patients. This review gives an overview about the current literature about cardiac troponins in prediction and identification of high-risk cancer patients. The overview is focusing on diagnostic challenges, biomarker significance, and gaps of knowledge. Latest publications highlight the relevance of cardiac troponin in risk analysis before cancer treatment as well as a potential diagnostic gatekeeper for further cardiological diagnostics and therapy.
No takes yet. Share an insight, caveat, or question.
Romann et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: